Skip to main content

Table 1 Noncytotoxic concentrations of chemotherapeutic agents (MTT assay)

From: Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

Chemotherapeutic agents EC*
LNCaP
EC
PCI-4B
EC
HCT-116
EC
HT-29
Antimicrotubule agents     
   Vinblastine (Velban) 100 nM 10 nM ND ND
   Vincristine (Oncovin) 100 nM 0.1 nM ND ND
   Paclitaxel (Taxol) 10 nM 0.1 nM 0.5 nM 5 nM
Antimetabolites     
   5-azacytidine (Vidaza) 100 nM 50 nM ND ND
   Methotrexate (Rheumatrex, Trexall) 5 nM 5 nM 0.5 nM ND
Alkylating agents     
   Cyclophosphamide (Cytoxan) Resistant** 50 nM 50 nM ND
   Mitomycin C (Mutamycin) 500 nM 50 nM ND ND
Topoisomerase inhibitors     
   Doxorubicin (Adriamycin) 100 nM 50 nM 5 nM 5 nM
Platinum agents     
   Cisplatin (Platinol) Resistant Resistant ND ND
   Carboplatin (Paraplatin) Resistant Resistant ND ND
Hormonal agents     
   Flutamide (Drogenil, Eulexin) Resistant Resistant ND ND
   Tamoxifen (Nolvadex) 1000 nM Resistant ND ND
Others     
   Bleomycin (Blenoxane) 100 nM 100 nM ND ND
  1. *, EC, Effective concentration – the maximal concentration of a chemotherapeutic agent that caused no inhibition of tumor cell activity in the MTT assay.
  2. **, Cells were considered resistant to the treatment when the EC value was greater than 1,000 nM.
  3. LNCaP, human prostate cancer cell line; PCI-4B, human head and neck squamous cell carcinoma cell line; HCT-116 and HT-29, human colon cancer cell lines; MTT, (3-(4,5-Dimmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction assay; ND, not determined.